Short answer
Stoke Therapeutics, Inc. (STOK) filed an 8-K current report with the SEC on April 7, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Board expanded to 10 directors with G. Clare Kahn, Ph.D. appointed as independent Class I director through the 2026 annual meeting.
Stoke Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded to 10 directors with G. Clare Kahn, Ph.D. appointed as independent Class I director through the 2026 annual meeting
- Kahn joins the Nominating and Corporate Governance Committee and chairs the Research and Development Committee
- Annual board retainer of $45,000, plus option for 30,782 shares
- Option target grant-date fair value approximately $724,000, vesting quarterly over three years
Item 7.01 · Regulation FD Disclosure
- April 7, 2026 press release announces Dr. Kahn’s appointment
- Appointment details and strategic relevance are contained in Exhibit 99.1
- Exhibit furnished under Regulation FD, limiting Exchange Act Section 18 liability and incorporation into registration statements
Item EX-99.1 · Exhibit EX-99.1
- Clare Kahn, Ph.D. appointed to Stoke’s Board, adding regulatory strategy and rare-disease development expertise
- Appointment supports Phase 3 advancement of zorevunersen, Stoke’s lead investigational Dravet syndrome therapy
- Zorevunersen targets underlying SCN1A-related protein deficiency; no approved disease-modifying Dravet therapies currently exist
- Potential addressable population estimated at up to 38,000 patients across the U.S., UK, EU-4 and Japan
- Biogen collaboration retains Stoke’s exclusive rights in the U.S., Canada and Mexico; Biogen holds rest-of-world rights
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Stoke Therapeutics, Inc. 8-K filings
Get the next STOK 8-K as it lands
Follow STOK for push alerts, or ask the research agent what this filing means.